Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Selective PP2A Enhancement through Biased Heterotrimer Stabilization
Daniel Leonard1, Wei Huang2, Sudeh Izadmehr3
1Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Abstract:
Impairment of protein phosphatases, including the family of serine/threonine phosphatases designated PP2A, is essential for the pathogenesis of many diseases, including cancer. The ability of PP2A to dephosphorylate hundreds of proteins is regulated by over 40 specificity-determining regulatory "B" subunits that compete for assembly and activation of heterogeneous PP2A heterotrimers. Here, we reveal how a small molecule, DT-061, specifically stabilizes the B56α-PP2A holoenzyme in a fully assembled, active state to dephosphorylate selective substrates, such as its well-known oncogenic target, c-Myc. Our 3.6 Å structure identifies molecular interactions between DT-061 and all three PP2A subunits that prevent dissociation of the active enzyme and highlight inherent mechanisms of PP2A complex assembly. Thus, our findings provide fundamental insights into PP2A complex assembly and regulation, identify a unique interfacial stabilizing mode of action for therapeutic targeting, and aid in the development of phosphatase-based therapeutics tailored against disease specific phospho-protein targets.
Insights
A novel molecule, DT-061, stabilizes the B56α-PP2A enzyme, enhancing its activity against cancer targets like c-Myc. This discovery offers new therapeutic strategies for diseases involving protein phosphatase 2A (PP2A) dysfunction.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Protein phosphatase 2A (PP2A) dysfunction is implicated in various diseases, including cancer.
- PP2A's activity is modulated by over 40 regulatory B subunits, influencing its substrate specificity and assembly into heterogeneous heterotrimers.
- Understanding PP2A complex assembly and regulation is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the mechanism of action of the small molecule DT-061.
- To elucidate how DT-061 stabilizes the B56α-PP2A holoenzyme.
- To provide insights into PP2A complex assembly and identify therapeutic targets.
Main Methods:
- 3.6 Å structural analysis of the DT-061 bound B56α-PP2A holoenzyme.
- Investigation of molecular interactions between DT-061 and PP2A subunits.
- Assessment of DT-061's effect on PP2A activity and substrate dephosphorylation.
Main Results:
- DT-061 specifically stabilizes the B56α-PP2A holoenzyme in an active conformation.
- The molecule engages all three PP2A subunits, preventing holoenzyme dissociation.
- DT-061 facilitates the dephosphorylation of specific substrates, including the oncogenic protein c-Myc.
Conclusions:
- DT-061 employs a unique interfacial stabilization mechanism for therapeutic targeting.
- The findings offer fundamental insights into PP2A complex assembly and regulation.
- This study aids in developing novel phosphatase-based therapeutics for diseases driven by aberrant protein phosphorylation.
Related Concept Videos
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Long-patch Base Excision Repair
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)
¹³C NMR: Distortionless Enhancement by Polarization Transfer (DEPT)
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

